| Issue | Title | |
| Vol 2008, No 94 (2008) | Dyax and Cubist Sign Deal for DX-88 Surgical Indications | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2007, No 90 (2007) | Dynavax Licenses HBV Vaccine to Merck & Co. | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 103 (2008) | Dynavax’s Deal Termination with Merck is followed by a New Agreement with GSK | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2020, No 5 (2020) | Dyno Therapeutics Launches with US$2 B Deals with Novartis and Sarepta | Abstract pdf html |
| Michelle Liu | ||
| Vol 2020, No 10 (2020) | Dyno Therapeutics Signs US$1.8 B Gene Therapy Pact with Roche | Abstract pdf html |
| Pratika Pahwa & Michelle Liu | ||
| Vol 2023, No 1 (2023) | Early Signs of M&A Activity Heating Up in 2023 | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2006, No 77 (2006) | Eastern Promise | Abstract html |
| Fintan Walton | ||
| Vol 2008, No 92 (2008) | Ebay | Details jpg |
| Business Review Editor | ||
| Vol 2014, No 2 (2014) | Edison and Dainippon Sumitomo Broaden Relationship with Discovery Alliance Targeting Redox Biochemistry | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 94 (2008) | Effective Benchmarking | Abstract |
| Business Review Editor | ||
| Vol 2014, No 3 (2014) | Eisai and Biogen Idec Partner to Advance Alzheimer’s Disease Drug Candidates | Abstract |
| Heather Cartwright | ||
| Vol 2016, No 2 (2016) | Eisai Bolsters Oncology Pipeline by Acquiring Rights to Huya’s Cancer Drug | Abstract pdf html |
| Jasmine Kalsi & Taskin Ahmed | ||
| Vol 2004, No 46 (2004) | Eisai Co. Ltd | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 2 (2013) | Eisai Divests US Rights to CTCL Therapy Targretin® to Valeant | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 91 (2008) | Eisai Takes Bold Step in MGI Acquisition | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 69 (2006) | Elan Grants Prialt™ Rights to Eisai | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 47 (2004) | Elan Streamlines CNS Portfolio with Divestment of Two Drugs | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 6 (2013) | Elan Strikes Series of Deals to Diversify and Stave Off Royalty Pharma | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 3 (2009) | Elan’s Shares Rise on Takeover Speculation | Abstract |
| Taskin Ahmed | ||
| Vol 2006, No 76 (2006) | Elaprase (idursulfase) | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 81 (2007) | Elbion in Deals for Neurological Products | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 80 (2007) | Elbion NV | Abstract |
| Business Review Editor | ||
| Vol 2010, No 7 (2010) | Eli Lilly Acquires Alnara Pharmaceuticals for Liprotamase | Abstract |
| Heather Cartwright | ||
| Vol 2018, No 5 (2018) | Eli Lilly Acquires ARMO BioSciences and AurKa Pharma Within a Week | Abstract pdf html |
| Natasha Piper | ||
| Vol 2017, No 2 (2017) | Eli Lilly acquires CoLucid to Expand Pain Portfolio | Abstract pdf html |
| Natasha Piper | ||
| Vol 2021, No 4 (2021) | Eli Lilly Acquires Gene Therapy Company Prevail Therapeutics for US$1.04 B | Abstract pdf html |
| Swati Sharan & Michelle Liu | ||
| Vol 2018, No 11 (2018) | Eli Lilly Bets Big on Dicerna’s Gene-Silencing Technology | Abstract pdf html |
| Michelle Liu | ||
| Vol 2022, No 1 (2022) | Eli Lilly Bolsters Metabolic Portfolio with Evotec and Abbisko Collaborations | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2020, No 12 (2020) | Eli Lilly Continues Neuroscience Expansion with US$1.36 B Disarm Therapeutics Buy | Abstract pdf html |
| Neha Madhwani & Michelle Liu | ||
| Vol 2005, No 65 (2005) | Eli Lilly Deals in Proteins and Antibodies | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 1 (2012) | Eli Lilly Joins ImmunoGen’s List of Big Pharma Collaborators | Abstract |
| Heather Cartwright | ||
| Vol 2002, No 29 (2002) | Eli Lilly Licenses Amylin Diabetes Treatment in US$325 M Deal | Abstract pdf |
| Business Review Editor | ||
| Vol 2023, No 3 (2023) | Eli Lilly Licenses Non-Opioid Pain Drug from Confo Therapeutics | Abstract pdf html |
| Lucy Haggerty | ||
| Vol 2018, No 8 (2018) | Eli Lilly Signs Multi-Year Deal with Anima Biotech for Translation Inhibitors | Abstract pdf html |
| Michelle Liu | ||
| Vol 2025, No 3 (2025) | Eli Lilly Signs US$1.2 B Collaboration with Magnet Biomedicine for Molecular Glue Therapeutics | Abstract pdf html |
| Amit Kaushik | ||
| Vol 2008, No 102 (2008) | Eli Lilly Steps Up Pharmacogenetics Effort | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2023, No 10 (2023) | Eli Lilly to Acquire Point Biopharma to Strengthen its Oncology Portfolio | Abstract pdf html |
| Shweta Gupta | ||
| Vol 2018, No 12 (2018) | Eli Lilly Turns to Tau Proteins with AC Immune Alzheimer’s Deal | Abstract pdf html |
| Subham Nandi | ||
| Vol 2008, No 101 (2008) | Eli Lilly Wins the ImClone Prize | Abstract pdf html |
| Sally Mardikian PhD | ||
| Vol 2008, No 99 (2008) | Eli Lilly’s Novel Financing Approach to R&D | Abstract pdf html |
| Helen Scrutton | ||
| Vol 2010, No 7 (2010) | Emergent BioSolutions Looks beyond Biodefence with Trubion Acquisition | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 2 (2012) | Enanta Pharmaceuticals Partners its Lead HCV NS5A Inhibitor with Novartis | Abstract |
| Heather Cartwright | ||
| Vol 2008, No 91 (2008) | Encouraging Entrepreneurialism | Abstract html |
| Fintan Walton | ||
| Vol 2025, No 3 (2025) | Endo and Mallinckrodt Set to Unite Through a US$6.7 B Merger | Abstract pdf html |
| Ayush Saxena | ||
| Vol 2009, No 1 (2009) | Endo Diversification Leads to Indevus Buyout | Abstract pdf html |
| Taskin Ahmed | ||
| Vol 2008, No 94 (2008) | Endo In-licenses Novartis Pain Product | Abstract pdf |
| Business Review Editor | ||
| Vol 2013, No 11 (2013) | Endo Looks to Geographic Expansion and Tax Advantages with US$1.6 B Paladin Buyout | Abstract |
| Heather Cartwright | ||
| Vol 2010, No 7 (2010) | Endo Pharmaceuticals Drives Growth in Pain Management with Acquisition of Penwest | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 4 (2011) | Endo to Acquire American Medical Systems and Advance its Diversification | Abstract |
| Heather Cartwright | ||
| Vol 2015, No 6 (2015) | Endo to Acquire Par Pharma for US$8.05 B to Become Top 5 US Generics Company | Abstract |
| Heather Cartwright & Rohit Khera | ||
| Vol 2010, No 8 (2010) | Endo to Acquire Qualitest and Expand its Generics Portfolio | Abstract |
| Heather Cartwright | ||
| Vol 2022, No 3 (2022) | Endpoint Health and Grifols Collaborate to Develop Antithrombin III for Sepsis | Abstract pdf html |
| Ayush Saxena & Lucy Haggerty | ||
| Vol 2012, No 11 (2012) | Ensemble Therapeutics Collaborates with Boehringer Ingelheim on Macrocyclic Drug Discovery | Abstract |
| Heather Cartwright | ||
| Vol 2005, No 57 (2005) | Entereg (alvimopan) | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 34 (2003) | EntreMed and Celgene | Abstract |
| Business Review Editor | ||
| Vol 2004, No 45 (2004) | Enzon and Inex to Commercialize Oncology Drug | Abstract pdf |
| Business Review Editor | ||
| Vol 2009, No 11 (2009) | Enzon Divests Specialty Business to Sigma-tau | Abstract |
| Taskin Ahmed | ||
| Vol 2007, No 87 (2007) | Enzon Pharmaceuticals Sells 25% Interest in Hepatitis C Drug | Abstract pdf |
| Business Review Editor | ||
| Vol 2002, No 29 (2002) | Enzon to Acquire North American and Japanese Rights to Elan Drug | Abstract pdf |
| Business Review Editor | ||
| Vol 2005, No 65 (2005) | Enzon: Reconstructing an Oncology Pipeline | Abstract |
| Business Review Editor | ||
| Vol 2002, No 30 (2002) | Enzon’s Acquisition of Abelcet | Abstract |
| Business Review Editor | ||
| Vol 2005, No 64 (2005) | EpiCept Merges with Maxim to Go Public | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 39 (2003) | Epigenomics AG | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 5 (2012) | Epizyme Collaborates with Celgene to Develop Epigenetics-Based Targeted Cancer Therapeutics | Abstract |
| Heather Cartwright | ||
| Vol 2011, No 3 (2011) | Epizyme Signs its Second Major Deal of 2011 | Abstract |
| Heather Cartwright | ||
| Vol 2022, No 2 (2022) | Equillium Acquires Bioniz Therapeutics to Strengthen Immunology Portfolio | Abstract pdf html |
| Ayush Saxena & Lucy Haggerty | ||
| Vol 2004, No 51 (2004) | Erbitux (cetuximab) | Abstract pdf |
| Business Review Editor | ||
| Vol 2004, No 47 (2004) | Eurand | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 85 (2007) | Europe United? | Abstract html |
| Fintan Walton | ||
| Vol 2004, No 50 (2004) | Europe's Need to Nurture Biotech | Details html |
| Fintan Walton | ||
| Vol 2006, No 77 (2006) | European Mid-Sized Pharma Consolidation Steps up a Gear | Abstract pdf |
| Business Review Editor | ||
| Vol 2008, No 94 (2008) | EUSA Pharma to Acquire Cytogen | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 7 (2012) | Evotec, Harvard and Janssen Form Three-Way Collaboration in Beta Cell Regeneration | Abstract |
| Heather Cartwright | ||
| Vol 2019, No 8 (2019) | Exact Sciences and Genomic Health to Merge in US$2.8 B Deal | Abstract html pdf |
| Michelle Liu | ||
| Vol 2005, No 61 (2005) | Exelixis and Genentech Forge R&D Pact | Abstract pdf |
| Business Review Editor | ||
| Vol 2016, No 3 (2016) | Exelixis Partners its Oncology Drug Cabozantinib with Ipsen for US$200 M Upfront | Abstract pdf html |
| Heather Cartwright & Jasmine Kalsi | ||
| Vol 2004, No 53 (2004) | Exelixis to Merge with X-Ceptor Therapeutics | Abstract pdf |
| Business Review Editor | ||
| Vol 2007, No 88 (2007) | Exelixis, Inc. | Abstract |
| Business Review Editor | ||
| Vol 2006, No 70 (2006) | Exelixis’ and Sankyo’s Cardiovascular Collaboration | Abstract pdf |
| Business Review Editor | ||
| Vol 2006, No 72 (2006) | ExonHit Therapeutics SA | Abstract |
| Business Review Editor | ||
| Vol 2009, No 6 (2009) | Expanding into Emerging Markets | Abstract |
| Taskin Ahmed | ||
| Vol 2008, No 93 (2008) | Expanding Large Molecule Capabilities: Teva#8217;s Latest Acquisition | Abstract pdf |
| Business Review Editor | ||
| Vol 2003, No 36 (2003) | Eyetech Pharmaceuticals Enters Deal to Market Pfizer’s Xalatan® | Abstract pdf |
| Business Review Editor | ||
| Vol 2020, No 5 (2020) | Fate Therapeutics Partners with Janssen for iPSC-derived Immunotherapies | Abstract pdf html |
| Michelle Liu | ||
| Vol 2002, No 29 (2002) | Ferrer to Distribute AVAX Vaccine in Europe/Latin America | Abstract pdf |
| Business Review Editor | ||
| Vol 2012, No 7 (2012) | Ferring Licenses Late-Stage Constipation Drug from AstraZeneca Spinout Albireo | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 4 (2009) | Financing Risk | Abstract |
| Fintan Walton | ||
| Vol 2004, No 46 (2004) | Fisher Scientific to Buy Oxoid and Dharmacon for US$410 M | Abstract pdf |
| Business Review Editor | ||
| Vol 2020, No 2 (2020) | Five Prime Signs US$530 M Licensing Deal with Seattle Genetics | Abstract html pdf |
| Michelle Liu | ||
| Vol 2007, No 81 (2007) | Flexibility and Fortune: AstraZeneca’s Strategic Shift | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 2 (2010) | Flexion Secures Licensing Deals with Major Pharmas | Abstract |
| Taskin Ahmed | ||
| Vol 2005, No 55 (2005) | Forest Bolsters its CNS Portfolio | Abstract |
| Business Review Editor | ||
| Vol 2014, No 5 (2014) | Forest Expands Gastrointestinal Portfolio with up to US$1.46 B Furiex Purchase | Abstract |
| Heather Cartwright | ||
| Vol 2012, No 6 (2012) | Forest Gains Takeover Option in Antibiotic Development Deal with Nabriva Therapeutics | Abstract |
| Heather Cartwright | ||
| Vol 2009, No 8 (2009) | Forest Inks Deals with Nycomed and AstraZeneca | Abstract |
| Taskin Ahmed | ||
| Vol 2011, No 3 (2011) | Forest Laboratories Agrees to Acquire Clinical Data for US$1.2 B Upfront | Abstract |
| Heather Cartwright | ||
| Vol 2004, No 53 (2004) | Forest Labs Licenses Respiratory Drug from Glenmark | Abstract pdf |
| Business Review Editor | ||
| Vol 2010, No 6 (2010) | Forest Licenses Novel Diabetes Compounds from TransTech Pharma | Abstract |
| Debbie Tranter | ||
| Vol 2008, No 93 (2008) | Forest Licenses Novexel’s Novel Broad-Spectrum Beta-Lactamase Inhibitor | Abstract pdf |
| Business Review Editor | ||
| Vol 2014, No 1 (2014) | Forest Looks to Rejuvenate with US$2.9 B Aptalis Purchase | Abstract |
| Heather Cartwright | ||
| 1001 - 1100 of 2613 Items | << < 6 7 8 9 10 11 12 13 14 15 > >> | |